Study year Follow-up Adverse events Clinical outcome Imaging outcome
  Months Major Improvement Stable Worsened Improvement Stable Worsened
Bonab, 2012 12 None 4/22 12/22 6/22 0/22 15/22 6/22
Connick, 2012 10 None 10/10 0/10 0/10 Not significant
Odianc, 2011 12 None 6/8 1/8 1/8      
Karussis, 2010 6 Transient aseptic
meningitis
15/15 0/15 0/15 15/15 0/15 0/15
Yamout, 2010 12 Transient encephalopathy
and seizure
5/7 1/7 1/7 0/7 2//7 5/7
Bonab, 2007 19 None 1/10 4/10 5/10 1/10 7/10 2/10
Riordan, 2009 12 None 3/3 0/3 0/3 0/3 3/3 0/3
Rice, 2011 12 None 6/6 0/6 0/6 6/6 0/6 0/6
Liang, 2009 12 None 1/1 0/1 0/1 1/1 0/1 0/1
Total: 6-19   51/82
(62%)
18/82
(22%)
13/82
(16%)
23/64
(36%)
27/64
(42%)
13/64
(20%)
Table 3: Outcome measures of the Stem Cell-Based Therapy clinical trials with MS patients